ARTS-023 / AVZO-023 (CDK4 selective inhibitor)
Provider 
Founded 2020
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private

Selective CDK4 inhibitor for HR+ breast cancer partnered with Avenzo.
ARTS-023 / AVZO-023 is an orally bioavailable CDK4 inhibitor with high selectivity over CDK6. Sub-nanomolar potency on CDK4/Cyclin D1, inhibits Rb phosphorylation and shows robust anti-tumor activity in ER+ models.
FDA IND clearance 2025. Phase 1 in US for advanced solid tumors in partnership with Avenzo (global development).
Pfizer

Atirmociclib (PF-07220060)
pfizer.com
Pfizer

Ibrance
pfizer.com
Eli Lilly and Company

Verzenio
lilly.com
Adds products that compete with one of ARTS-023 / AVZO-023 (CDK4 selective inhibitor)’s direct competitors but not with ARTS-023 / AVZO-023 (CDK4 selective inhibitor) itself. They are shaded, and Linked Through names the direct competitor each one competes with.
| Attribute | ARTS-023 / AVZO-023 (CDK4 selective inhibitor) | Atirmociclib (PF-07220060) | Ibrance | Verzenio | |
|---|---|---|---|---|---|
| Provider | |||||
| Founded | 2020 | 1849 | 1849 | 1876 | |
| Sells To | Enterprise | Non-Profit | Non-Profit | Consumers, Enterprise | |
| Pricing Model | Recurring, Software | Recurring | Recurring | Recurring, Software, Transactional | |
| Ownership | Private | Private | Private | Public |
Provider 
Founded 2020
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private
Provider 
Founded 1849
Sells To Non-Profit
Pricing Model Recurring
Ownership Private
Provider 
Founded 1849
Sells To Non-Profit
Pricing Model Recurring
Ownership Private
Provider 
Founded 1876
Sells To Consumers, Enterprise
Pricing Model Recurring, Software, Transactional
Ownership Public


Pfizer's CDK2-selective inhibitor in Phase 1/2 development for HR+/HER2- metastatic breast cancer.


Incyte's selective oral CDK2 inhibitor in Phase 1 development for advanced solid tumors.
Pfizer's CDK2-selective inhibitor in Phase 1/2 development for HR+/HER2- metastatic breast cancer.

Incyte's selective oral CDK2 inhibitor in Phase 1 development for advanced solid tumors.
